<DOC>
	<DOCNO>NCT03068910</DOCNO>
	<brief_summary>This study address hypothesis , late pubertal girl hyperandrogenemia , androgens antagonize progesterone 's ability suppress wake LH pulse frequency . All participant receive 4 dos progesterone ; half participant pretreated androgen receptor blockade ( spironolactone , 50 mg twice daily ) , half pretreated placebo ( twice daily ) .</brief_summary>
	<brief_title>Hyperandrogenemia Altered Day-night LH Pulse Patterns</brief_title>
	<detailed_description>Late pubertal obese girl hyperandrogenemia alter day-night pattern LH secretion compare without hyperandrogenemia . In addition , previous study reveal late pubertal adolescent hyperandrogenemia demonstrate impaired suppression LH pulse frequency estradiol progesterone administration one week . This study address overall work model hold daytime/waking LH pulse frequency acutely suppress progesterone negative feedback testosterone concentration low , daytime/waking LH pulse frequency resistant progesterone negative feedback testosterone concentration high . The hypothesis , late pubertal girl hyperandrogenemia , progesterone suppression wake LH frequency great set androgen receptor blockade ( spironolactone , 50 mg twice daily ) compare placebo condition . Sixteen late pubertal girl ( postmenarcheal , 4 year ) Tanner stage-specific hyperandrogenemia undergo two CRU admission separate least 4 week . During admission , acute effect oral micronized progesterone ( 0.8 mg/kg 1000 , 1600 , 2200 h ) LH pulse frequency assess . Subjects randomize pretreated 2 week either spironolactone ( androgen receptor blocker commonly use hyperandrogenism ) placebo prior first admission ; subject pretreated medication ( placebo spironolactone ) 2 week second admission accordance cross-over design . Wake LH pulse frequency spironolactone placebo admission analyze via hierarchical linear mixed model .</detailed_description>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<criteria>Late pubertal girl ( i.e. , postmenarcheal , ≤ 4 year ) Hyperandrogenism , define elevated Tanner stagespecific free testosterone concentration and/or clinical evidence hirsutism Age &lt; 10 &gt; 17 year ( study design elucidate mechanism underlie emerge PCOS late pubertal , postmenarcheal adolescent girl ) Men boy exclude ( study design elucidate mechanism underlie HA emerge PCOS peripubertal adolescent girl ) Inability comprehend do study do Obesity associate diagnose ( genetic ) syndrome ( e.g. , PraderWilli syndrome , leptin deficiency ) , obesity relate medication ( e.g. , glucocorticoid ) , etc . To ensure blood withdrawal within safe limit , weight &lt; 28.1 kg exclusion criterion . Since underweight alter pulsatile LH secretion , BMIforage percentile &lt; 5 exclusion criterion . Positive pregnancy test lactation . Subjects positive pregnancy test inform result screen physician . Under Virginia law , parental notification require minor . However , screen physician encourage subject tell parent ( ) . We counsel adolescent importance appropriate prenatal care/counseling . We offer appropriate followup Teen Health Clinic UVA and/or encourage adolescent secure prompt care via primary care physician 's office . Virilization total testosterone &gt; 150 ng/dl ( confirmed repeat ) , suggest possibility virilize neoplasm DHEAS &gt; 1.5 time ageappropriate upper limit normal ( confirmed repeat ) Congenital adrenal hyperplasia ( CAH ) : A morning 17hydroxyprogesterone ( 17OHP ) &gt; 300 ng/dl ( confirmed repeat ) suggest possibility CAH . If obtain luteal phase ( evidence high progesterone ) , 17OHP repeat 08000900 h early follicular phase ( , oligomenorrheic , follicular phase—confirmed low serum progesterone ) . If 17OHP &gt; 300 ng/dl confirm repeat testing , ACTHstimulated 17OHP &lt; 1000 ng/dl require study participation . Morning cortisol concentration &lt; 3 µg/dL ( confirm repeat ) , history adrenal insufficiency , symptom suggestive adrenal insufficiency ( e.g. , persistent anorexia , nausea , unintentional weight loss , etc . ) Evidence Cushing 's syndrome history physical exam ( e.g. , history impaired growth ) Any abnormal TSH concentration trigger repeat test . In many case TSH initially abnormal , repeat TSH normal . These subject permit continue study . If TSH remain abnormal repeat testing , subject refer primary medical provider . In case , participant 's primary medical provider elect simply observe mildly low ( &gt; 0.1 ) mildly elevate ( &lt; 10 ) stable . In case , accept TSH 0.3 7 ( inclusive ) remain stable least 6 months—such TSH value exceedingly unlikely influence central reproductive axis influence risk study . Notably , subject reasonablytreated primary hypothyroidism—reflected TSH value 0.3 7—on stable dose thyroid hormone ( i.e. , dose least 2 month ) exclude . Prolactin concentration &gt; 30 ng/mL ( confirmed repeat ) Persistent hemoglobin &lt; 11.5 g/dL nonAfrican American subject ; hemoglobin &lt; 11.0 g/dL African American subject ( confirm repeat ) . Importantly , documentation hemoglobin ≥ 11.0 g/dL African American subject ≥ 11.5 g/dL nonAfrican American subject month prior CRU admission require frequent sample protocol CRU . A previous diagnosis diabetes , fast glucose ≥ 126 mg/dl , hemoglobin A1c ≥ 6.5 % ( confirmed repeat ) Elevated creatinine concentration and/or estimate glomerular filtration rate &lt; 80 mL/min/1.73 m2 ( confirmed repeat ) Persistently abnormal sodium potassium concentration ( confirmed repeat ) Bicarbonate concentration &lt; 20 &gt; 30 ( confirm repeat ) Liver test abnormality ( confirm repeat ) , two exception : ( 1 ) mild bilirubin elevation accept set know Gilbert 's syndrome subject 's primary care provider provide presumptive diagnosis Gilbert 's syndrome plan workup ; ( 2 ) mild transaminase ( ALT , AST ) elevation may see obese girl , stable elevation &lt; 1.5 time upper limit normal accept group . Significant history cardiac pulmonary dysfunction ( e.g. , know suspect congestive heart failure ; asthma require intermittent systemic corticosteroid ; etc . ) Personal history deep venous thrombosis ( DVT ) Personal history ovarian , endometrial , breast neoplasia Absolute contraindication spironolactone use include anuria , acute renal insufficiency , significant impairment renal excretory function , hyperkalemia , primary adrenal insufficiency ( Addison 's disease ) , concomitant use eplerenone</criteria>
	<gender>Female</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>PCOS</keyword>
</DOC>